Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Time to recurrence, defined as the time between randomization to treatment in the double-blind period and the first documentation of a recurrence.
Change in PANSS total and subscale scores from randomization to each visit and to the end of the study. Change from baseline in CGI-S at each assessment time point and at endpoint. Incidence of adverse events throughout study.
18 Years to 65 Years (Adult)
July 1, 2004
June 8, 2011
† Study has passed its completion date and status has not been verified in more than two years.